Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study

Table 4 Baseline patient characteristics (patients grouped according to treatment order)

Characteristics	EZE + BEZA		BEZA + EZE		BEZA & EZE
Characteristics	n	mean ± SD/%	n	mean ± SD/%	n	mean ± SD/%
Age (years)	174	62.5 ± 12.9	257	59.2 ± 12.0	228	61.2 ± 14.2
Men (%)	94	54.0	173	67.3	117	51.3
With complications (%)	152	87.4	220	85.6	179	78.5
Concurrent disease
Hypertension (%)	106	60.9	141	54.9	121	53.1
Diabetes (%)	61	35.1	100	38.9	69	30.3
Hepatic disease (%)	34	19.5	68	26.5	50	21.9
Cardiac disease (%)	8	4.6	19	7.4	19	8.3
Renal disease (%)	2	1.1	8	3.1	10	4.4
Purpose of combination therapy^a
Primary prevention (%)	152	87.4	245	95.3	207	90.8
Secondary prevention (%)	5	2.9	11	4.3	10	4.4
Unknown (%)	17	9.8	1	0.4	11	4.8
Concomitant medications
Drugs for hypertension (%)	104	59.8	141	54.9	110	48.2
Drugs for diabetes (%)	44	25.3	72	28.0	47	20.6
Statin (%)	3	1.7	4	1.6	7	3.1

Data are expressed as mean ± standard deviation or n and percent.
^aDefined according to the Guidelines for the Prevention of Atherosclerotic Cardiovascular Disease 2007 [9]. EZE + BEZA: patients who were already taking ezetimibe and then added bezafibrate at the start of the study; BEZA + EZE: patients who were already taking bezafibrate and then added ezetimibe at the start of the study; BEZA & EZE: patients who started bezafibrate and ezetimibe concurrently.

ISSN: 1475-2840